BioInvent

287 articles about BioInvent

• Transgene and BioInvent Joint JITC Publication Demonstrates the Potential of BT-001 Oncolytic Virus to Provide Therapeutic Benefit Beyond Current Anti-PD1/ Anti-CTLA-4 Immune Checkpoint Blockade

  1/20/2022

  Transgene and BioInvent International AB jointly announced the publication of extensive preclinical proof-of-concept data for BT-001 in the Journal for ImmunoTherapy of Cancer.

• BioInvent: The FDA Grants Orphan Drug Designation to BI-1206 for the Treatment of Follicular Lymphoma

  1/19/2022

  BioInvent International AB announces that its anti-FcyRllB antibody BI-1206 has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the treatment of follicular lymphoma, the most common form of slow-growing Non-Hodgkin lymphoma.

• BioInvent Appoints Experienced Industry Leader Marie Moores as Chief Operating Officer

  1/18/2022

  BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces the appointment of Marie Moores as Chief Operating Officer.

• BioInvent Moves to NASDAQ Stockholm’s Mid Cap Segment - Dec 20, 2021

  12/20/2021

  BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces that the company will be moved to the Mid Cap segment on Nasdaq Stockholm from January 3, 2022.

• BioInvent announces positive early data from ongoing solid cancer trial of BI-1206 in combination with pembrolizumab

  12/17/2021

  BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces positive early data from the ongoing clinical study of its novel anti-FcyRIIB antibody BI-1206 in combination with anti-PD-1 therapy pembrolizumab for the treatment of patients with solid tumors.

• BioInvent’s Latest NHL Data at ASH Show Increased and Sustained Responses to BI-1206 in Relapsed Patients

  12/11/2021

  BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces updated positive interim top-line data from its novel anti-FcyRIIB antibody BI-1206 that show increased response levels and sustained complete responses.

• BioInvent and CASI Pharmaceuticals Announce CTA Approval for Clinical Studies of BI-1206 in NHL in China

  12/10/2021

  BioInvent International AB today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA), China's medical product regulator, has approved a Clinical Trial Application (CTA) submitted by BioInvent's licensee in China, CASI Pharmaceuticals (CASI).

• BioInvent has Submitted a CTA for a Phase 1/2a trial of BI-1607, a Novel anti-FcyRIIB Antibody for the Treatment of Patients with Solid Tumors

  12/8/2021

  BioInvent International AB, a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, announces it has submitted a Clinical Trial Application for the novel, fully human FcyRIIB-blocking antibody, BI-1607.

• Nomination Committee Appointed for BioInvent International’s Annual General Meeting 2022

  11/25/2021

  The members of the Nomination Committee for BioInvent International AB:s Annual General Meeting in 2022 have now been appointed.

• BioInvent Hosting Key Opinion Leader Webinar on BI-1206

  11/23/2021

  BioInvent International that it will host a key opinion leader (KOL) webinar Friday, December 17 at 1 pm ET (7 pm CET).

• BioInvent and Transgene present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021

  11/9/2021

  BioInvent International AB and Transgene announce preclinical data supporting the mode of action of BT-001, their novel dual mechanism-of-action oncolytic Vaccinia Virus.

• Transgene and BioInvent Present Preclinical Data Highlighting the Robust Anti-Tumoral Activity of BT-001 Oncolytic Virus at SITC 2021

  11/9/2021

  Transgene and BioInvent Present Preclinical Data Highlighting the Robust Anti-Tumoral Activity of BT-001 Oncolytic Virus at SITC 2021

• CASI Pharmaceuticals Partner, BioInvent, To Present Further Positive Clinical Data On BI-1206 At ASH 2021

  11/5/2021

  CASI Pharmaceuticals, Inc. announced additional positive interim top-line data from its novel anti-FcγRIIB antibody BI-1206.

• BioInvent to Show Further Positive BI-1206 Clinical Data in December at ASH 2021

  11/4/2021

  BioInvent International AB today announces additional positive interim top-line data from its novel anti-FcγRIIB antibody BI-1206.

• Invitation to Presentation of BioInvent’s Interim Report January–September 2021

  10/28/2021

  BioInvent International AB invites to a presentation of the third quarter report 2021 and a telephone conference with CEO Martin Welschof.

• BioInvent International AB Interim Report January - September 2021

  10/28/2021

  The powerful combination of BioInvent's R&D and in-house manufacturing provides invaluable support to our clinical development and facilitates the execution of our current clinical portfolio.

• BioInvent Appoints Immunotherapy Expert Alexander Eggermont to Scientific Advisory Board

  10/25/2021

  BioInvent International today announces the appointment of the renowned immunotherapy expert Alexander Eggermont MD, PhD, as a member of its Scientific Advisory Board.

• BioInvent and Transgene to present preclinical data on BT-001 oncolytic virus at SITC 2021

  10/1/2021

  BioInvent International AB and Transgene announce that they will present additional preclinical data on their novel dual mechanism-of-action oncolytic Vaccinia virus BT-001 at the 36th Annual Meeting of the Society for Immunotherapy of Cancer in November 2021.

• BioInvent International AB: Interim report January-June 2021

  8/26/2021

  BioInvent announced a second clinical trial collaboration and supply agreement with Merck to evaluate BI-1808 in combination with Keytruda® (pembrolizumab) in patients with advanced solid tumors.

• BioInvent Announces Second Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1808 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

  8/6/2021

  BioInvent International AB announced that it has entered into a second clinical trial collaboration and supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA, to evaluate the combination of BioInvent's BI-1808, one of its proprietary anti-TNFR2 antibodies and MSD's anti-PD-1 therapy, KEYTRUDA in a Phase 1/2a clinical trial for patients with lung cancer and ovarian cancer.